PDCD1 and T-cell non-Hodgkin lymphoma: Pembrolizumab is a programmed cell death protein 1 (PD-1) inhibitor that has been shown to have activity in r/r PTCL, especially with the increased PD-1expression in a variety of NK/T-cell lymphomas by malignant T cells [21].